DEA History Topical Treatment 
Canna Law Blog
NOVEMBER 27, 2021
So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” MDMA (Ecstasy) Nears FDA Approval for PTSD Treatment.
United Patients Group
APRIL 3, 2023
Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment. Cannabis is a schedule 1 substance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 28, 2022
Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Controlled Substance Schedules , DRUG ENF’T ADMIN., [link] [ [link] ] (defining DEA criteria for categorization in Schedule I and listing psychedelic examples such as lysergic acid diethylamide (LSD), peyote, and MDMA).
The Cannigma
JULY 3, 2023
Canada and Australia have already passed legislation allowing for MDMA use for mental health treatment. Sometimes insufflated Inhalation, oral, topical, sublingual and transdermal Other names E, X, Ecstasy, Molly, XTC, The Love Drug Weed, marijuana, pot, ganja, dope, grass… the list goes on.
SpeedWeed
MARCH 18, 2021
Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. They also wrote: The study sample included participants with a history of cannabis use.
Cannabis Law Report
JULY 1, 2021
In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions.
Cannabis Law Report
SEPTEMBER 23, 2019
The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. The AAFP recognizes the benefits of intervention and treatment for the recreational use of marijuana, in lieu of incarceration, for all individuals, including youth.
Expert insights. Personalized for you.
87 
Let's personalize your content